Literature DB >> 19954359

Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.

Pieter Rottiers1, Tim De Smedt, Lothar Steidler.   

Abstract

Lactic acid bacteria are a group of taxonomically diverse, Gram-positive food-grade bacteria that have been safely consumed throughout history. The lactic acid bacterium Lactococcus lactis, well-known for its use in the manufacture of cheese, can be genetically engineered and orally formulated to deliver therapeutic proteins in the gastrointestinal tract. This review focuses on the genetic engineering of Lactococcus lactis to secrete high-quality, correctly processed bioactive molecules derived from a eukaryotic background. The therapeutic applications of these genetically modified strains are discussed, with special regards to immunomodulation.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19954359     DOI： 10.3109/08830180903197498

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN： 0883-0185            Impact factor:   5.311


  9 in total

1.  Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Authors:  Tatiana Takiishi; Hannelie Korf; Tom L Van Belle; Sofie Robert; Fabio A Grieco; Silvia Caluwaerts; Letizia Galleri; Isabella Spagnuolo; Lothar Steidler; Karolien Van Huynegem; Pieter Demetter; Clive Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Conny Gysemans; Chantal Mathieu
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

2.  Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.

Authors:  Romain Hardet; Benjamin Chevalier; Léa Dupaty; Yassine Naïmi; Gaëtan Riou; Laurent Drouot; Laetitia Jean; Anna Salvetti; Olivier Boyer; Sahil Adriouch
Journal:  Mol Ther       Date:  2015-08-12       Impact factor: 11.454

Review 3.  Gene-environment interactions in chronic inflammatory disease.

Authors:  Harald Renz; Erika von Mutius; Per Brandtzaeg; William O Cookson; Ingo B Autenrieth; Dirk Haller
Journal:  Nat Immunol       Date:  2011-04       Impact factor: 25.606

Review 4.  Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.

Authors:  Atefeh Afchangi; Tayebeh Latifi; Somayeh Jalilvand; Sayed Mahdi Marashi; Zabihollah Shoja
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

5.  Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling.

Authors:  Felix Hugentobler; Karen K Yam; Joshua Gillard; Raya Mahbuba; Martin Olivier; Benoit Cousineau
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

Review 6.  Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes.

Authors:  Olivia Cano-Garrido; Joaquin Seras-Franzoso; Elena Garcia-Fruitós
Journal:  Microb Cell Fact       Date:  2015-09-16       Impact factor: 5.328

Review 7.  Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease.

Authors:  Yaron Ilan
Journal:  Clin Transl Immunology       Date:  2016-01-29

8.  Recombinant CRAMP-producing Lactococcus lactis attenuates dextran sulfate sodium-induced colitis by colonic colonization and inhibiting p38/NF-κB signaling.

Authors:  Jiahong Li; Shiwen Yu; Xiaohua Pan; Ming Zhang; Zhuwu Lv; Li-Long Pan; Jia Sun
Journal:  Food Nutr Res       Date:  2021-09-28       Impact factor: 3.894

9.  Oral Tolerance Induced by Heat Shock Protein 65-Producing Lactococcus lactis Mitigates Inflammation in Leishmania braziliensis Infection.

Authors:  Priscila Valera Guerra; Camila Mattos Andrade; Ivanéia Valeriano Nunes; Brena Cardoso Gama; Rafael Tibúrcio; Washington Luis Conrado Santos; Vasco Ariston Azevedo; Natalia Machado Tavares; Juliana de Souza Rebouças; Tatiani Uceli Maiolii; Ana Maria Caetano Faria; Cláudia Ida Brodskyn
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.